GlassScriptPhysician profile
Richard Curtin
NPI 1013989607
$1,346.25
in general payments reported to CMS, 2019-2025
26 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $56.73 · 2021: $175 · 2022: $482 · 2023: $105 · 2024: $87.03 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $242 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $241.82 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $114.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $232.90 | 2019-2022 | |
| Ethicon US, LLC | $166.79 | 2019-2024 | Surgiflo Hemostatic Matrix, Dermabond Prineo |
| Pacira Pharmaceuticals Incorporated | $127.82 | 2019 | |
| Abbvie INC. | $114.66 | 2024-2025 | |
| Bard Peripheral Vascular, INC. | $100.90 | 2019-2022 | |
| Davol INC. | $66.73 | 2021 | |
| Kci USA, INC. | $61.27 | 2021-2023 | Activ.A.C. |
| Merck Sharp & Dohme LLC | $61.19 | 2020-2023 | Zerbaxa, Dificid |
| Vertex Pharmaceuticals Incorporated | $44.02 | 2025 | |
| Paratek Pharmaceuticals, INC. | $37.07 | 2021-2025 | Nuzyra |
| Smith+Nephew, INC. | $34.87 | 2019-2022 | |
| Cumberland Pharmaceuticals, INC. | $34.16 | 2019-2023 | Vibativ |
| Allergan, INC. | $29.24 | 2022 | |
| Tei Biosciences INC | $25.82 | 2019 | |
| Silk Road Medical, INC. | $24.17 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $22.26 | 2022 | |
| Mentor Worldwide LLC | $21.22 | 2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Solventum Corporation | $20.37 | 2025 | Prevena, V.A.C. Veraflo |
| Janssen Pharmaceuticals, INC | $19.86 | 2022 | |
| Depuy Synthes Sales INC. | $17.74 | 2022 | |
| Sanara Medtech INC. | $17.44 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.99 | 2022 | |
| Tela Bio, INC. | $14.60 | 2020 | |
| Reapplix INC. | $14.14 | 2022 | |
| Medtronic Vascular, INC. | $12.02 | 2020 | |
| Intra-Sana Laboratories | $10.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Curtin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.